{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T13:01:47Z","timestamp":1781010107843,"version":"3.54.1"},"reference-count":13,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2014,12,1]],"date-time":"2014-12-01T00:00:00Z","timestamp":1417392000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Mathematical Biosciences"],"published-print":{"date-parts":[[2014,12]]},"DOI":"10.1016\/j.mbs.2014.09.006","type":"journal-article","created":{"date-parts":[[2014,9,19]],"date-time":"2014-09-19T12:22:59Z","timestamp":1411129379000},"page":"11-18","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"special_numbering":"C","title":["Benefits of hepatitis C virus treatment: A balance of preventing onward transmission and re-infection"],"prefix":"10.1016","volume":"258","author":[{"given":"A.S.","family":"de Vos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.E.E.","family":"Kretzschmar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.mbs.2014.09.006_bib0001","first-page":"423","article-title":"HIV and HCV infection among injecting drug users","volume":"67","author":"Hagan","year":"2000","journal-title":"Mt. Sinai J. Med."},{"key":"10.1016\/j.mbs.2014.09.006_bib0002","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1111\/liv.12063","article-title":"Best strategies for global HCV eradication","volume":"33","author":"Hagan","year":"2013","journal-title":"Liver Int."},{"key":"10.1016\/j.mbs.2014.09.006_bib0003","unstructured":"B. Malhotra (Ed.), The Strategic Use of Antiretrovirals for Treatment and Prevention of HIV Infection: 2nd Expert Panel Meeting Meeting Report. WHO\/HIV\/2013."},{"key":"10.1016\/j.mbs.2014.09.006_bib0004","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1016\/j.jhep.2010.08.029","article-title":"Can antiviral therapy for hepatitis C reduce the prevalence of HCV among injecting drug user populations? A modeling analysis of its prevention utility","volume":"54","author":"Martin","year":"2011","journal-title":"J. Hepatol."},{"key":"10.1016\/j.mbs.2014.09.006_bib0005","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0022309","article-title":"Optimal control of hepatitis C antiviral treatment programme delivery for prevention amongst a population of injecting drug users","volume":"6","author":"Martin","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.mbs.2014.09.006_bib0006","doi-asserted-by":"crossref","first-page":"638","DOI":"10.5694\/mja11.10981","article-title":"Modelling antiviral treatment to prevent hepatitis C infection among people who inject drugs in Victoria","volume":"196","author":"Hellard","year":"2012","journal-title":"Med. J. Aust."},{"issue":"e34548","key":"10.1016\/j.mbs.2014.09.006_bib0007","article-title":"Treatment of hepatitis C as prevention: A modeling case study in Vietnam","volume":"7","author":"Durier","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.mbs.2014.09.006_bib0008","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1002\/hep.24656","article-title":"Cost-effectiveness of hepatitis C virus antiviral treatment for injection drug user populations","volume":"55","author":"Martin","year":"2012","journal-title":"Hepatology"},{"key":"10.1016\/j.mbs.2014.09.006_bib0009","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.drugalcdep.2010.03.006","article-title":"Optimal targeting of Hepatitis C virus treatment among injecting drug users to those not enrolled in methadone maintenance programs","volume":"110","author":"Zeiler","year":"2010","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.mbs.2014.09.006_bib0010","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.drugalcdep.2010.08.001","article-title":"Can Hepatitis C virus treatment be used as a prevention strategy? Additional model projections for Australia and elsewhere","volume":"113","author":"Vickerman","year":"2011","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.mbs.2014.09.006_bib0011","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.epidem.2012.01.001","article-title":"Determinants of persistent spread of HIV in HCV-infected populations of injecting drug users","volume":"4","author":"de Vos","year":"2012","journal-title":"Epidemics"},{"key":"10.1016\/j.mbs.2014.09.006_bib0012","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1177\/1355819613485671","article-title":"A normative perspective on discounting health outcomes","volume":"18","author":"Oliver","year":"2013","journal-title":"J. Health Serv. Res. Policy"},{"key":"10.1016\/j.mbs.2014.09.006_bib0013","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1097\/00002030-199405000-00001","article-title":"A circulation theory of needle exchange","volume":"8","author":"Kaplan","year":"1994","journal-title":"AIDS"}],"container-title":["Mathematical Biosciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002555641400176X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002555641400176X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,29]],"date-time":"2018-09-29T12:20:21Z","timestamp":1538223621000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S002555641400176X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,12]]},"references-count":13,"alternative-id":["S002555641400176X"],"URL":"https:\/\/doi.org\/10.1016\/j.mbs.2014.09.006","relation":{},"ISSN":["0025-5564"],"issn-type":[{"value":"0025-5564","type":"print"}],"subject":[],"published":{"date-parts":[[2014,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Benefits of hepatitis C virus treatment: A balance of preventing onward transmission and re-infection","name":"articletitle","label":"Article Title"},{"value":"Mathematical Biosciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mbs.2014.09.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}